Metraipolis › archive › dc_7d3ea8ce19a2

Plasma Proteome-Driven Liquid Biopsy for Individualized Monitoring and Risk Stratification of Immune-Related Adverse Events in Checkpoint Immunotherapy — Europe PMC PMID:41391830

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41391830
DOI
10.1016/j.mcpro.2025.101488
License (as archived)
solo-consultazione
Archived
2026-11-07T16:15:15.646Z
SHA-256 of the archived text
cc003d5927d57f302f710d1a8c22c20d673b4340d0a714e0db745b79dffdb671
Stable URL of this page
https://metraipolis.com/documento/dc_7d3ea8ce19a2

How to cite

Plasma Proteome-Driven Liquid Biopsy for Individualized Monitoring and Risk Stratification of Immune-Related Adverse Events in Checkpoint Immunotherapy — Europe PMC PMID:41391830 — Europe PMC (en), https://europepmc.org/article/MED/41391830 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7d3ea8ce19a2 (Metraipolis archive dc_7d3ea8ce19a2, sha256 cc003d5927d57f302f710d1a8c22c20d673b4340d0a714e0db745b79dffdb671)
BibTeX
@misc{dc7d3ea8ce19a2,
  title = {Plasma Proteome-Driven Liquid Biopsy for Individualized Monitoring and Risk Stratification of Immune-Related Adverse Events in Checkpoint Immunotherapy — Europe PMC PMID:41391830},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41391830},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7d3ea8ce19a2; sha256 cc003d5927d57f302f710d1a8c22c20d673b4340d0a714e0db745b79dffdb671},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41391830. Agents can read the archived copy with the MCP tool read_document.